Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Journal of Clinical Oncology · 2024-09 · 42 (25) · 3000-3011
DOI: 10.1200/jco.24.00720 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024-09. Verfasst von D Ross Camidge und 32 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Cancer Center, Aurora, CO. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536 ) aimed to identify the optimal c-Met protein–overexpressing non–small cell lung cancer (NSCLC) population for treatment with Teliso-V (stage I) and expand the selected group for efficacy evaluation (stage II). Stage II enrolled patients with nonsquamous epidermal growth factor receptor ( EGFR )-wildtype NSCLC. METHODS Eligible patients had locally advanced/metastatic c-Met protein–overexpressing NSCLC and ≤2 previous lines of therapy (including ≤1 line of systemic chemotherapy). c-Met protein overexpression in nonsquamous EGFR -wildtype NSCLC was defined as ≥25% tumor cells with 3+ staining (high [≥50% 3+]; intermediate [≥25%–
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Colorado Cancer Center, Aurora, CO.
- Sheba Medical Center, Ramat Gan, Israel.
- National Cancer Center Hospital, Tokyo, Japan.
- David Geffen School of Medicine at UCLA, Los Angeles, CA.
- St Petersburg Napalkov Cancer Center, St Petersburg, Russia.
- Center of Palliative Medicine De Vita, St Petersburg, Russia.
ORCID-Profile: D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko, Irfan Cicin, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Aaron S Mansfield, Chih-Hsi Kuo, Kazumi Nishino, Se-Hoon Lee, David Planchard, Shun Lu
Zitieren
APA
Camidge, D. R., Bar, J., Horinouchi, H., Goldman, J., Moiseenko, F., Filippova, E., Cicin, I., Ciuleanu, T., Daaboul, N., Liu, C., Bradbury, P., Moskovitz, M., Katgi, N., Tomasini, P., Zer, A., Girard, N., Cuppens, K., Han, J. Y., Wu, S. Y., …, & Lu, S. (2024). Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of Clinical Oncology, 42(25), 3000-3011. https://doi.org/10.1200/jco.24.00720
Vancouver
Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, et al. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of Clinical Oncology. 2024;42(25):3000-3011. doi:10.1200/jco.24.00720
BibTeX
@article{Camidge2024,
author = {Camidge, D Ross and Bar, Jair and Horinouchi, Hidehito and Goldman, Jonathan and Moiseenko, Fedor and Filippova, Elena and Cicin, Irfan and Ciuleanu, Tudor and Daaboul, Nathalie and Liu, Chunling and Bradbury, Penelope and Moskovitz, Mor and Katgi, Nuran and Tomasini, Pascale and Zer, Alona and Girard, Nicolas and Cuppens, Kristof and Han, Ji-Youn and Wu, Shang-Yin and Baijal, Shobhit and Mansfield, Aaron S and Kuo, Chih-Hsi and Nishino, Kazumi and Lee, Se-Hoon and Planchard, David and Baik, Christina and Li, Martha and Ansell, Peter and Xia, Summer and Bolotin, Ellen and Looman, Jim and Ratajczak, Christine and Lu, Shun},
title = {Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {25},
pages = {3000--3011},
doi = {10.1200/jco.24.00720}
}
EUVIMED